131 related articles for article (PubMed ID: 6927369)
21. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.
Nabekura T; Nagasawa T; Nakauchi H; Onodera M
Cancer Immunol Immunother; 2008 May; 57(5):611-22. PubMed ID: 17786440
[TBL] [Abstract][Full Text] [Related]
22. Surface antigen on Ehrlich ascites tumor cells.
Pessina A; Brambilla P; Mocarelli P
Biomedicine; 1980; 33(4):105-9. PubMed ID: 7000194
[TBL] [Abstract][Full Text] [Related]
23. Rejection of lethal tumors after subcutaneous inoculation: a phenomenon of antigenic expression?
Apffel CA; Peters JH
J Natl Cancer Inst; 1967 Dec; 39(6):1129-39. PubMed ID: 4170428
[No Abstract] [Full Text] [Related]
24. Specific and non-specific immunotherapy of Ehrlich Ascites Carcinoma in mice.
Jakóbisiak M; Kańtoch M; Lasek W; Dobaczewska H; Obłakowski P
Folia Biol (Krakow); 1982; 30(3-4):91-7. PubMed ID: 7166197
[No Abstract] [Full Text] [Related]
25. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
26. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
27. Passive immunotherapy of mice bearing Ehrlich ascites tumor expressing human, membrane-bound placental alkaline phosphatase.
Barka T; Henderson S; van der Noen HM
Tumour Biol; 2000; 21(3):145-52. PubMed ID: 10754465
[TBL] [Abstract][Full Text] [Related]
28. [Tolerance induction by passage of the antigen with tumor cells].
Bundschuh G
Radiobiol Radiother (Berl); 1983; 24(4):525-30. PubMed ID: 6647799
[No Abstract] [Full Text] [Related]
29. IgG generated against benign tumor-associated antigens prevented the effects of 1,2-dimethylhydrazine in rats.
Zusman I; Zusman R; Karol D; Gurevich P
Anticancer Res; 1996; 16(3A):1183-6. PubMed ID: 8702233
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Ehrlich ascites tumor growth by nucleoprotein. II. In vivo fate of the tumor cells.
Bradshaw LJ; Webb DR
J Natl Cancer Inst; 1969 Sep; 43(3):527-32. PubMed ID: 4980604
[No Abstract] [Full Text] [Related]
31. [Study of the antigenic affinity between bacillus megaterium H. and ehrlich cancer cells in an anaphylaxis reaction with desensitization].
Zatula DG; Severnikov VA
Mikrobiol Zh; 1976; 38(2):220-4. PubMed ID: 820951
[No Abstract] [Full Text] [Related]
32. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae).
Da Silva SL; Chaar Jda S; Yano T
Eur J Pharmacol; 2009 Apr; 608(1-3):76-83. PubMed ID: 19222998
[TBL] [Abstract][Full Text] [Related]
33. [Different immunological factors in the therapy of an experimental tumor].
Nicolin A; Frontini E; Olivani P
Boll Ist Sieroter Milan; 1971; 50(4):295-8. PubMed ID: 5163498
[No Abstract] [Full Text] [Related]
34. Saccharomyces cerevisiae, the Baker's Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice.
Ghoneum M; Badr El-Din NK; Noaman E; Tolentino L
Cancer Immunol Immunother; 2008 Apr; 57(4):581-92. PubMed ID: 17891396
[TBL] [Abstract][Full Text] [Related]
35. Expression and function of beta 1 integrins on adherent and nonadherent Ehrlich ascites tumor cells.
Song Z; Varani J; Goldstein IJ
Exp Cell Res; 1995 May; 218(1):96-104. PubMed ID: 7537699
[TBL] [Abstract][Full Text] [Related]
36. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
37. Adaptation of Ehrlich ascites carcinoma cells to energy deprivation in vivo can be associated with heat shock protein accumulation.
Kabakov AE; Molotkov AO; Budagova KR; Makarova YuM ; Mosin AF; Gabai VL
J Cell Physiol; 1995 Oct; 165(1):1-6. PubMed ID: 7559791
[TBL] [Abstract][Full Text] [Related]
38. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
39. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
